Safety and Effectiveness of Baricitinib in Chinese Patients with Moderate-to-Severe Rheumatoid Arthritis: 24-Week Results from a Post-Marketing Safety Study

Abstract Introduction Baricitinib, a JAK1/JAK2 inhibitor, is approved for treatment of moderate-to-severe rheumatoid arthritis (RA) in China. This single-arm, prospective, multi-center, post-marketing safety study (PMSS) evaluated the safety and effectiveness of baricitinib in Chinese patients. Meth...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Chan-yuan Wu, Qian Wang, Jian Shi, Xiu-ying Zhang, Rong Du, Jie-ruo Gu, Qi-huan Liu, Jiao Yu, Jia-wei Xu, Yan-jie Zhang, Hao Zhu, Meng-tao Li, Xiao-feng Zeng
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Adis, Springer Healthcare 2023-09-01
Serie:	Rheumatology and Therapy
Soggetti:	Pharmacovigilance Effectiveness Rheumatoid arthritis (RA) Baricitinib Janus kinase (JAK) inhibitor
Accesso online:	https://doi.org/10.1007/s40744-023-00596-4
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!